Despite considerable challenges, RNA interference (RNAi) as a therapeutic strategy continues to draw excitement and scrutiny. Two recent meetings—Select Biosciences’ “RNAi and miRNA World Congress” ...

When chemists get involved with siRNA delivery, they want to do more than just find new materials to take therapeutic nucleic acids to their targets. They want to understand how those materials work. ...

Most siRNA oligonucleotides (oligos) for in vivo use are chemically synthesized duplexes of 21 to 23 oligos based on the original work of Tuschl and colleagues. 4, 5 Although chemical modifications ...

The current coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has challenged healthcare facilities globally. Even though the FDA ...

Despite the Nobel Prize-winning discovery of RNA interference (RNAi) over a decade ago and the billions of dollars spent developing therapeutic applications, delivery issues continue to challenge the ...

We have focused on developing histidine-lysine (HK) polymers as carriers of nucleic acids including siRNA. To this end, we developed a series of such polymers with specific sequences and branching. 10 ...

Small interfering RNAs (siRNAs) are novel therapeutics that can be used to treat a wide range of diseases. This has led to a growing demand for selective, efficient, and safe ways of delivering siRNA ...

In a study published in Cell Reports Physical Science on Nov. 25, a research team led by Prof. CAI Lintao from the Shenzhen Institutes of Advanced Technology (SIAT) of the Chinese Academy of Sciences ...

This means that siRNA demonstrates significant potential for therapeutic use, given its capacity to control protein levels. However, one of the main drawbacks with siRNA is that researchers have had ...

In a new study published in the Cell Research, Chen-Yu Zhang's group at Nanjing University reports "In vivo self-assembled small RNA is the new generation of RNAi therapeutics". The development of ...